Moir D, Poon R, Yagminas A, Park G, Viau A, Valli V E, Chu I
Bureau of Chemical Hazards, Department of Health, Ottawa, ON, Canada.
J Environ Sci Health B. 1997 Jul;32(4):545-64. doi: 10.1080/03601239709373102.
The subchronic toxicity of acridine was investigated in rats following dietary exposure at 0, 1, 10, 100 and 500 ppm for 13 weeks. The growth rate and food consumption were not affected by treatment and no clinical signs of toxicity were observed. There was a slight but significant decrease in spleen weight, both in absolute terms and as a percent of body weight, in the 500 ppm males and a slight increase in absolute thymus weight in the females of the same dose group. Both hepatic ethoxyresorufin O-deethylase (EROD) and pentoxyresorufin O-dealkylase (PROD) activities were slightly, but significantly, elevated in females in the 500 ppm dose group. No haematological or other biochemical changes were observed. Females also displayed dose-related increases in inorganic phosphate and uric acid levels. Treatment-related histopathological changes were seen in the thyroid, liver and kidney and included hepatic anisokaryosis and vesiculation of nuclei and glomerular adhesions, reticulin sclerosis and nuclear pyknosis in the kidney. Residue data showed a dose-dependent accumulation of acridine in liver, kidney and adipose with the highest concentration being found in the fat of the 500 ppm dose group. Based on these data, the no observable adverse effect level of acridine was judged to be 100 ppm or 12 mg/kg bw/day.
在大鼠中进行了吖啶的亚慢性毒性研究,大鼠经口摄入浓度为0、1、10、100和500 ppm的吖啶,持续13周。处理对生长速率和食物消耗量没有影响,未观察到毒性的临床体征。500 ppm剂量组的雄性大鼠脾脏重量绝对值和占体重百分比均略有但显著下降,同一剂量组的雌性大鼠胸腺重量绝对值略有增加。500 ppm剂量组雌性大鼠的肝脏乙氧基异吩恶唑酮O -脱乙基酶(EROD)和戊氧基异吩恶唑酮O -脱烷基酶(PROD)活性均略有但显著升高。未观察到血液学或其他生化变化。雌性大鼠的无机磷酸盐和尿酸水平也呈现出与剂量相关的升高。在甲状腺、肝脏和肾脏中观察到与处理相关的组织病理学变化,包括肝脏的核大小不等和核空泡化以及肾小球粘连、肾脏的网状纤维硬化和核固缩。残留数据表明,吖啶在肝脏、肾脏和脂肪中呈剂量依赖性蓄积,500 ppm剂量组脂肪中的浓度最高。基于这些数据,吖啶的无可见不良反应水平被判定为100 ppm或12 mg/kg bw/天。